Results 251 to 260 of about 38,022 (310)

Association of GLP-1 Receptor Agonist Use With Risk of Lumbar Degenerative Disease and Spine Surgery in Patients With Type 2 Diabetes: A Propensity Score-matched Cohort Study. [PDF]

Global Spine J
Chang Y, Chi KY, Song J, Chen CM, Lin HM.   +4 more
europepmc   +1 more source

The Cautious Promise of GLP-1 Receptor Agonists

Ochsner Journal
openaire   +2 more sources

Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder. [PDF]

Toxins (Basel)
Hammad MAM, Quesada SG, Belczyk AL, Ghoniem GM.   +3 more
europepmc   +1 more source

GLP-1 receptor agonist for weight loss and fertility: Social media and online perception versus evidence-based medicine. [PDF]

PLoS One
Merhi Z, Karekar M, Mouanness M.
europepmc   +1 more source

Chronically elevated sympathetic nervous system tone: A significant, common, and poorly realised contributor to cardiometabolic disease in type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1595-1598, March 2026.
Ralph A. DeFronzo
wiley   +1 more source

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP‐1R agonist survodutide in mice

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2437-2442, March 2026.
Fen Long, Tenagne D. Challa, Vissarion Efthymiou, Manuel Klug, Thomas Klein, Heike Neubauer, Christian Wolfrum, Carla Horvath   +7 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

GLP-1 receptor agonists today

Diabetes Research and Clinical Practice, 2011
Type 2 diabetes mellitus (T2DM) is a complex, progressive disease affecting an estimated 257 million people worldwide. A number of unmet needs exist with traditional T2DM therapies, which can lead to insufficient glycaemic control and increased risk of diabetes-associated complications.
Michel, Marre, Alfred, Penfornis
openaire   +2 more sources

Emerging GLP-1 receptor agonists

Expert Opinion on Emerging Drugs, 2011
Recently, glucagon-like peptide-1 receptor (GLP-1R) agonists have become available for the treatment of type 2 diabetes. These agents exploit the physiological effects of GLP-1, which is able to address several of the pathophysiological features of type 2 diabetes.
Lund, Asger, Knop, Filip K, Vilsbøll, Tina   +2 more
openaire   +3 more sources